A spirited and might I add spicy 🌶️ debate this morning at #ATC2026 on whether we should use #GLP-1s in decompensated #cirrhosis for weight loss to facilitate #LiverTransplant
An exciting area in need of much more research. Amazing graphic made by Babak Orandi for the debate
Hi #LICOP family! Are you presenting at @ATCMeeting ? We’d love to promote your🔥presentations!
Please complete this brief form https://t.co/FyJi9l1Yhk by📅Fri 6/19
You can also post & tag @AST_LICOP—we’ll RT ASAP
See you soon in Boston 🫶 #LiverTwitter#TransplantTwitter
Proud that @UCSD_GI is ranked #1 globally in Research & Education in the latest U.S. News rankings powered by Clarivate. Testament to our incredible faculty, trainees, staff & collaborators driving innovation and impact every day.
https://t.co/DyOOuITVUK
LICOP is excited to highlight our members’ 🔥presentations at #ATC2026!
Join us in supporting our colleagues and celebrating the outstanding work being shared throughout @ATCMeeting
See the slides for presentation times and locations⬇️
#LiverTwitter#TransplantTwitter
Today, we recognize both Global #FattyLiverDay and #WorldMASHDay while embracing the updated #liverdisease nomenclature.
AASLD is proud to have helped shape the international consensus that led to the adoption of more accurate, patient-centered terminology. What was once known as #fattyliverdisease is now part of the broader category of steatotic liver disease #SLD, including metabolic dysfunction-associated steatotic liver disease #MASLD, and metabolic dysfunction-associated steatohepatitis #MASH.
The updated terminology supports more precise research, diagnosis, and communication in #hepatology.
Learn more about the nonmenclature change: https://t.co/s6gmIhKUST
Registration is open for our Liver Q&A Webinar on understanding and managing MASLD/MASH (#fattyliverdisease). Featuring Dr. @MonicaTincopa and a special #GlobalFattyLiverDay panel with experts, public health, community leaders, and patient voices. Register: https://t.co/wZoed3YLA7
Registration is open for our Liver Q&A Webinar on understanding and managing MASLD/MASH (#fattyliverdisease). Featuring Dr. @MonicaTincopa and a special #GlobalFattyLiverDay panel with experts, public health, community leaders, and patient voices. Register: https://t.co/wZoed3YLA7
Honored to present an update on our work looking at Precision Medicine efforts to improve screening, risk stratification and treatment of #SLD in #Hispanic#Latinx adults at our annual @UCSDHealth@UCSD_GI research retreat
And just like that…
The time you do a Meet the Professor session on #NITs & therapeutics in #MASLD & #MASH@DDWMeeting with your former fellowship director.
Great session discussing diagnosis, risk stratification & treatment🙌
Super⭐️ @UCSDHealth resident @SRamanujan98 presenting guideline concordant use #statins in adults at risk of #MASLD and #MASH
💠24% of pts not on statin met an indication
💠those with statin indication but not rx had more advanced #fibrosis
💠 #obesity predictor of no statin rx
What does the pathway to #LiverTransplant look like for #Hispanic#Latino patients? @DDWMeeting
Analysis of ~10,000 pts referred for liver txp
💠<50% of Latino pts referred were listed
💠<30% transplanted
💠 ascites & social support associated with access to liver txp
One of my favorite parts of #DDW2026 — participating in the @LiGaH panel today. Always glad to help invest in the next generation of gastroenterologists. So energized by these trainees. 🔥 @AmerGastroAssn
AASLD members at Digestive Disease Week® 2026: Join us TONIGHT at the Members' Reception! Connect across our member community and hear special announcements that will elevate the future of hepatology.
🕡 Sunday, May 3, 6:30–8:30 PM
📍 720 Lounge, Hilton Chicago